Summary & Overview
HCPCS J1628: Injection of guselkumab, 1 mg
HCPCS Level II code J1628 designates the injectable biologic guselkumab, billed per 1 mg unit. Guselkumab is a monoclonal antibody used in specialty dermatology and rheumatology care, and its accurate coding is important for claims processing, benefit determination, and tracking utilization of high-cost biologic therapies nationally. This code matters because biologic injections drive substantial specialty drug spend and require clear unitization for appropriate reimbursement and inventory management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations, typical sites of service for administration, and common billing practices that affect claim acceptance.
Readers will find benchmarks for unit-based billing and service line classification, an overview of clinical context for guselkumab administration, and notes on common claim-level issues such as unit reporting and place-of-service alignment. The piece also summarizes how payers typically treat injectable biologics in outpatient and office-based settings and highlights operational considerations for billing teams and revenue cycle staff.
Data not available in the input is noted where applicable, and the content focuses on national-level implications rather than state-specific policy.
Billing Code Overview
HCPCS Level II code J1628 represents an injection of guselkumab, billed per 1 mg unit. The service is a pharmacologic injectable therapy typically used in outpatient infusion or clinic settings where biologic agents are administered, including specialty infusion centers, physician offices, and hospital outpatient departments.
Service Type: Injectable biologic medication administration
Typical Site of Service: Outpatient infusion center, specialty clinic, or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is a 42-year-old with moderate-to-severe plaque psoriasis who has previously failed or had an inadequate response to topical therapies and conventional systemic agents. The patient arrives at an outpatient infusion or injection clinic (physician office, hospital outpatient clinic, or specialty biologics infusion center) for administration of a weight-based or fixed-dose biologic. The billed item J1628 represents 1 mg of guselkumab, a subcutaneously administered monoclonal antibody targeting IL-23, supplied in prefilled syringe or vial form.
Before the visit, the clinic verifies prior authorization, documents diagnosis codes supporting medical necessity, and performs medication reconciliation and screening for active infection or tuberculosis. On arrival, a registered nurse confirms identity, documents vital signs, and inspects the intended subcutaneous injection site. The nurse prepares the appropriate number of J1628 units per the prescribed dose (e.g., 100 mg dose would be billed as one hundred units of J1628). The dose is administered subcutaneously with standard aseptic technique. Post-injection observation is brief (typically 15–30 minutes) to monitor for immediate hypersensitivity. Documentation includes lot number, expiration, any unused portion (with modifier JW if drug discarded), and the associated ICD-10 diagnosis codes supporting the indication. Typical sites of service: physician office, outpatient hospital clinic, and specialty infusion/injection centers.
Coding Specifications
| Modifier | Description |
|---|